Stock Ratings / Health Care / ADXN / forecast

XBIO (47) APUS (43) CANF (31) PULM (36) ⌘ Pro Terminal →

Addex Therapeutics Ltd (ADXN) 12-Month Stock Forecast & Price Target Cone

$2.93 -1.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.92

Addex Therapeutics Ltd (ADXN) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $5.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.92 (-0.37%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-0.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADXN)Realized 20D OHLCV Swing Band: ±12.3%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY ADXN SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$3.22-14.3% Next Q

Q2 (-2Q)

Grade C+$2.76+7.6% Next Q

Q3 (-1Q)

Grade C$2.97-1.3% Next Q

Current

Grade D+$2.93-0.2% Hist 90D α

Trajectory: C+ (65) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ADXN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, ADXN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.33) or 200D SMA ($5.80) invalidates the momentum regime and cuts Target Base ($2.92) toward Bear Floor ($2.28).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADXN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ADXN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ADXN Position Size: $10,000

Shares at $2.93: 3413.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.28

$7,782

$-2,218 (-22.2%)

12M Consensus BaseTarget $2.92

$9,966

$-34 (-0.3%)

12M Bull Case BreakoutTarget $10.95

$37,372

+$27,372 (+273.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$10	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADXN)

✓Walkthrough of ADXN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADXN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.90%▼ DESCENDING CHANNEL

2026-10-30O $3.08H $3.15L $2.93C $2.93VOL 2.6K

RES: $5.11SUP: $1.43SMA50: $3.33SMA200: $5.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADXN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADXN Butterfly Map → + Track ADXN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADXN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADXN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADXN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADXN)

Health Care Rank #259 of 1016 ⚔️ XBIO vs ADXN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADXN vs. XBIO, APUS, CANF, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Addex Therapeutics Ltd (ADXN) ranks #259 by composite RQD confidence (57/100, grade D+) and #947 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, ADXN leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADXN ACTIVE Addex Therapeutics Ltd	D+	57/100	—	—	—	-1.01%	$5.0M	Benchmark Subject
XBIO Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	/xbio-vs-adxn →
APUS Apimeds Pharmaceuticals US Inc.	D-	43/100	—	—	-6.2%	+4.56%	$5.0M	/apus-vs-adxn →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-adxn →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-adxn →

2. ADXN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Addex Therapeutics Ltd (ADXN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ADXN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADXN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Addex Therapeutics Ltd (NASDAQ: ADXN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.93 (-1.01% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADXN ranks #259 in composite RQD confidence.

How does ADXN compare to XBIO and APUS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADXN carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XBIO (Xenetic Biosciences Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M) and APUS (Apimeds Pharmaceuticals US Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -6.2%, cap $5.0M). Among the 5-stock peer group, ADXN leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADXN?

For Addex Therapeutics Ltd (ADXN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #259 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADXN trading relative to its 50-day, 200-day, and 52-week technical levels?

ADXN last traded at $2.93 (-1.01% on volume of 2,366 shares), positioning the stock -12.01% below its 50-day simple moving average ($3.33) and -49.48% below its 200-day simple moving average ($5.80). Across its 52-week range of $2.56 to $10.43, ADXN sits at the 4.7% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($2.57 to $3.29).

ADXN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ADXN's 12-month stock price target?

Addex Therapeutics Ltd (ADXN) carries a 12-month consensus base price target of $2.92 (-0.3% from $2.93), with a bull-case target of $10.95 and a bear-case floor of $2.28.